BioSpace News Archive

Fact.MR – A Market Research and Competitive Intelligence Provider: As per a recent market analysis by Fact.MR, the global computer-aided detection market is poised to expand at a healthy 9.8% CAGR, surpassing a valuation of US$ 1.1 Bn over the forecast period 2020 to 2025.

Major biotechnology, pharmaceutical, and research organizations maintain a library of millions of compounds to facilitate their drug discovery and development processes.

Current research directions in the upper limb prosthetics market hover around improving the performance outcomes so that the devices meet the functional requirements in amputees.

AMO Pharma Limited, a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited or no treatment options, announced that Julia Jones has joined the company as chief financial officer and a member of the Company’s board of directors.

Abalos Therapeutics announced an extension to its Series A funding round bringing the total raised in this round to EUR 43 million.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will release third-quarter 2021 financial results before the market opens on Thursday, October 28, 2021, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

Caris Life Sciences® and Ono Pharmaceutical Co., Ltd. announced a strategic collaboration to leverage Caris’ best-in-class molecular profiling, including its novel, liquid biopsy circulating nucleic acids sequencing assay, across several studies beginning later this year.

NRx Pharmaceuticals, announced the publication of peer-reviewed results from a prospective, open-label, administratively controlled trial of aviptadil for the treatment of respiratory failure in patients with Critical COVID-19.

Blade Therapeutics, Inc. today announced that the FDA has granted orphan drug designation for cudetaxestat for the potential treatment of systemic sclerosis (SSc). Cudetaxestat is an investigational non-competitive autotaxin inhibitor in clinical development for IPF.

Element Nutritional Sciences Inc. will hold a conference call at 4pm ET today, October 14, 2021, to provide an update on its operational performance for the three-month period ending September 30, 2021 (“Q3 2021”).